Q-omics provides the consensus-scored UBL4B profile across patient tissues and cancer cell-line models. UBL4B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, UBL4B is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, UBL4B RNA expression shows 8,129 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight ACC, KIRC, and PAAD as cancer lineages where UBL4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBL4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBL4B survival associations across molecular data types. UBL4B RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBL4B RNA expression–survival associations across cancer types. High UBL4B expression shows unfavorable associations in ACC, THCA, KIRP and KIRC, but favorable associations in CESC and STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for UBL4B RNA expression.
This table summarizes UBL4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for UBL4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBL4B shows lower tumor expression in BRCA and UCEC and higher tumor expression in KIRC, COAD, LIHC and CHOL. The KIRC box plot shows higher UBL4B RNA expression in tumor versus normal tissue (log2 FC = +0.071, t-test p = .001).
This table shows molecular features associated with UBL4B in patient tissues and cancer cell lines. In patient samples, UBL4B shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set. In cancer cell lines, UBL4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
